Mj. Burke et Sh. Preskorn, Therapeutic drug monitoring of antidepressants - Cost implications and relevance to clinical practice, CLIN PHARMA, 37(2), 1999, pp. 147-165
Despite evidence to support its potential benefit in clinical practice, the
rapeutic drug monitoring (TDM) is under-utilised and underdeveloped in the
field of psychiatry. In antidepressant pharmacotherapy drug dose is emphasi
sed as the critical treatment variable. However, dose in, and of, itself ca
n be a strikingly misleading predictor of drug concentration and, hence, tr
eatment effect. For antidepressant drugs, plasma concentrations at a given
dose have been shown to vary in excess of 40-fold. The clinical relevance o
f this variability is that at a standard antidepressant dosage only some pa
tients will have tissue drug concentrations associated with an optimal resp
onse whereas others will have either low, ineffective drug concentrations o
r unnecessarily high concentrations which may be poorly tolerated.
Among clinicians and healthcare agencies there is an under-appreciation of
the degree of pharmacokinetic variability found in patients and how that mi
ght impact on the patients response to pharmacotherapy. Hence there is a pe
rception that TDM is an unnecessary, complicated and costly procedure. This
is actually unfounded. There are data to suggest that TDM can favourably a
ffect the outcome of antidepressant treatment by providing a rational alter
native to the inherently slower, trial and error practice of dosage titrati
on based on clinical response.
It is unlikely that TDM will become a standard of care for all antidepressa
nt agents and all patients. Therefore the question becomes for which antide
pressant agents, for which patients and under what circumstances, is TDM mo
re cost-effective than traditional dose titration. The use of TDM to optimi
se the efficient use of selected antidepressant agents could potentially fr
ee up healthcare resources to fund other equally deserving treatments. This
article provides a discussion of the major classes of antidepressant drugs
with regard to their pharmacological features that predict the utility of
TDM in clinical practice. Recommendations are made for the practical applic
ation of TDM and the directions for further research.